A practical reference on reduced glutathione: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-10-28 and is reviewed periodically as new material appears.
Glutathione is a small tripeptide built from glutamate, cysteine, and glycine. The peptide bond between glutamate and cysteine uses the gamma-carboxyl group, a linkage that resists ordinary peptidases. Cells make it in two ATP-dependent steps: gamma-glutamylcysteine synthetase joins glutamate and cysteine, then glutathione synthetase adds glycine. The pathway is feedback-inhibited by glutathione itself, so intracellular levels tend to stay within a narrow range. Because cysteine is often limiting, sulfur amino acid supply influences how much glutathione a cell can produce.
In its reduced form, glutathione carries a sulfhydryl group that can donate electrons. This property lets it act as a major cellular antioxidant and redox buffer. Glutathione peroxidase uses it to reduce hydrogen peroxide and lipid peroxides, while glutathione reductase regenerates the reduced form using NADPH. The ratio of reduced glutathione to glutathione disulfide is widely used as an indicator of oxidative stress, though the ratio changes with compartment, cell type, and sample handling. Oxidized glutathione can also form mixed disulfides with proteins, affecting their activity.
Glutathione is a small tripeptide built from glutamic acid, cysteine, and glycine. Its peptide bond between glutamate and cysteine involves the gamma-carboxyl group rather than the usual alpha-carboxyl group. This structure gives the molecule a reactive thiol on the cysteine residue. The reduced form, often abbreviated GSH, is the predominant intracellular species in many cell types. Because the thiol can donate electrons, glutathione participates in redox chemistry and in the conjugation of reactive molecules.
Cells synthesize glutathione through two ATP-dependent steps: glutamate-cysteine ligase joins glutamate and cysteine, and glutathione synthetase adds glycine to form the complete tripeptide. Breakdown occurs through gamma-glutamyl transpeptidase and subsequent peptidase reactions, forming the gamma-glutamyl cycle. Within cells, glutathione also forms a disulfide-linked dimer called GSSG when two GSH molecules react. The balance between GSH and GSSG is widely used as an indicator of oxidative conditions, although the ratio can vary by compartment and tissue.
| Property | Value | Notes |
|---|---|---|
| Chemical formula | C10H17N3O6S | Refers to the reduced form |
| Molar mass | 307.32 g/mol | Calculated for the neutral molecule |
| Appearance | White crystalline powder | Often hygroscopic; protect from moisture |
| Water solubility | Soluble in water | Reported values vary with purity and form |
| Alternative names | GSH, reduced glutathione | GSH specifies the thiol form |
Glutathione is a tripeptide composed of glutamate, cysteine, and glycine. Its cysteine residue carries a thiol group, which allows the molecule to participate in reduction and oxidation reactions. The compound exists in most living cells, where the reduced form, often abbreviated GSH, is usually more abundant than the oxidized disulfide form, GSSG. Intracellular concentrations are commonly in the millimolar range, while extracellular concentrations are much lower. This uneven distribution supports its role as a major cellular redox buffer.
Cells synthesize glutathione through two ATP-dependent enzymatic steps. The first step combines glutamate and cysteine to form gamma-glutamylcysteine, catalyzed by glutamate-cysteine ligase. The second step adds glycine, producing the complete tripeptide, catalyzed by glutathione synthetase. Glutathione itself can inhibit the first enzyme, providing negative feedback when levels are high. Because cysteine is often limiting, its availability influences how quickly the pathway proceeds. These reactions occur in the cytosol, and the resulting glutathione can be distributed to other compartments.
Biosynthesis occurs in two ATP-dependent steps. The enzyme glutamate-cysteine ligase joins glutamate and cysteine, forming gamma-glutamylcysteine; glutathione synthetase then adds glycine to produce the complete tripeptide. Because the peptide bond from glutamate uses the gamma-carboxyl group, glutathione resists digestion by many ordinary peptidases. Tissues vary in synthesis capacity, and the liver generally contains high concentrations relative to many other organs. This uneven distribution contributes to organ-specific differences in redox buffering and affects how experimental results are interpreted across tissue types.
Glutathione participates in detoxification reactions, amino acid transport, and the maintenance of protein thiols. It serves as a cofactor for several enzymes, including glutathione peroxidases and glutathione S-transferases. In research literature, altered glutathione status appears in studies of aging, infection, metabolic stress, and environmental exposure. Whether low glutathione is a cause, consequence, or marker of such conditions often remains unresolved. Direct measurement in blood or tissue provides a snapshot, but results depend on sample handling, timing, and the method used.
=== Aggregation of safety data during clinical development === Aggregating safety data across clinical trials during drug development is important because trials are generally designed to focus on determining how well the drug works. The safety data collected and aggregated across multiple trials as the drug is developed allows the sponsor, investigators and regulatory agencies to monitor the aggregate safety profile of experimental medicines as they are developed. The value of assessing aggregate safety data is: a) decisions based on aggregate safety assessment during development of the medicine can be made throughout the medicine's development and b) it sets up the sponsor and regulators well for assessing the medicine's safety after the drug is approved.
This differs from a case of constant extraction field where the ions are accelerated instantaneously upon being formed. Delayed extraction is used with MALDI or laser desorption/ionization (LDI) ion sources where the ions to be analyzed are produced in an expanding plume moving from the sample plate with a high speed (400–1000 m/s). Since the thickness of the ion packets arriving at the detector is important to mass resolution, on first inspection it can appear counter-intuitive to allow the ion plume to further expand before extraction. Delayed extraction is more of a compensation for the initial momentum of the ions: it provides the same arrival times at the detector for ions with the same mass-to-charge ratios but with different initial velocities. In delayed extraction of ions produced in vacuum, the ions that have lower momentum in the direction of extraction start to be accelerated at higher potential due to being further from the extraction plate when the extraction field is turned on. Conversely, those ions with greater forward momentum start to be accelerated at lower potential since they are closer to the extraction plate. At the exit from the acceleration region, the slower ions at the back of the plume will be accelerated to greater velocity than the initially faster ions at the front of the plume. So after delayed extraction, a group of ions that leaves the ion source earlier has lower velocity in the direction of the acceleration compared to some other group of ions that leaves the ion source later but with greater velocity.
To slow this metabolic degradation and improve the drug's pharmacokinetic profile, researchers sought to replace the highly oxidizable pyridyl groups with more electron-deficient heterocyclic. This led to the following key structural optimizations:
Sources: en.wikipedia.org
=== Blood tests === A variety of blood tests are available for analyzing cholesterol transport behavior, HDL, LDL, triglycerides, lipoprotein little a, homocysteine, C-reactive protein, blood sugar control: fasting, after eating or averages using glycated albumen or hemoglobin, myoglobin, creatine kinase, troponin, brain-type natriuretic peptide, etc. to assess the evolution of coronary artery disease and evidence of existing damage. A great many more physiologic markers related to atherosclerosis and heart function are used and being developed and evaluated in research.
Early attempts to create alien-human hybrids were pioneered by German and Japanese scientists shortly after World War II, and for some time during the Cold War. However, these often met with failure, and the Syndicate started to rely more on their own scientists. According to the Alien Bounty Hunter, in the 1950s, Soviet geneticists found a unique genetic anomaly within identical twins. The Colonists and Syndicate scientists used this to eventually develop human clones with alien elements and partial hybrids, but they were still ultimately inferior. Hybrids of this type include Samantha Mulder, Kurt Crawford, the Gregors, Ernest Calderon, and Dr. William Secare. Child and adult versions of Samantha and Kurt are also seen. These clones have the same caustic greenish blood of the aliens, have greater muscular strength and higher physical endurance levels than most normal humans, and can breathe underwater. In addition to their intended use by the alien colonists, the Syndicate is occasionally seen using these clones to perform various tasks, such as research and physical labor. The pinnacle of the project is Cassandra Spender (Veronica Cartwright), mother of Jeffrey Spender (Chris Owens) and ex-wife of The Smoking Man. Cassandra is a hybrid created through a process other than cloning, and worked on by both the Syndicate and the aliens themselves, although the exact methods used to transform her are never fully revealed. The experiment presumably began when she, along with other family members of the Syndicate, were turned over to the colonists in 1973.
The European Food Safety Authority (EFSA) refers to the collective set of information as Dietary Reference Values, with Population Reference Intake (PRI) instead of RDA, and Average Requirement instead of EAR. AI and UL are defined the same as in the United States. For women and men of ages 15 and older, the PRIs are set respectively at 650 and 750 μg RE/day. PRI for pregnancy is 700 μg RE/day, for lactation 1300/day. For children of ages 1–14 years, the PRIs increase with age from 250 to 600 μg RE/day. These PRIs are similar to the US RDAs. The EFSA reviewed the same safety question as the United States, and set ULs at 800 for ages 1–3, 1100 for ages 4–6, 1500 for ages 7–10, 2000 for ages 11–14, 2600 for ages 15–17 and 3000 μg/day for ages 18 and older for preformed vitamin A, i.e., not including dietary contributions from carotenoids.
Sources: en.wikipedia.org
It is a tripeptide of glutamate, cysteine, and glycine. The glutamate-cysteine bond is unusual because it forms through the gamma-carboxyl group.
It reflects the balance between oxidant exposure and antioxidant capacity. The ratio is not a direct clinical diagnosis and depends on the tissue and sample method.
No. It also participates in detoxification, amino acid transport, and protein modification. Its roles vary by cell type and compartment.
It is a tripeptide of glutamic acid, cysteine, and glycine. The linkage between glutamate and cysteine uses the gamma-carboxyl group, which is unusual for peptides.